Application seeking approval of amivantamab for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations submitted to the US FDA

Amivantamab is a human EGFR and mesenchymal epithelial transition factor (MET) antibody that targets tumours with activating and resistance EGFR and MET mutations and amplifications. The submission is for use in disease that has progressed on or after platinum-based chemotherapy

Source:

Biospace Inc.